Technical Analysis for SESN - Sesen Bio, Inc.
|Grade||Last Price||% Change||Price Change|
SESN closed down 8.0 percent on Thursday, January 17, 2019, on 2.45 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical SESN trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||New 52 Week Closing Low||Bearish||0.00%|
|Jan 17||New 52 Week Low||Weakness||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Down 3 Days in a Row||Weakness||0.00%|
|Jan 17||Oversold Stochastic||Weakness||0.00%|
|Jan 16||New 52 Week Closing Low||Bearish||-8.00%|
|Jan 16||Narrow Range Bar||Range Contraction||-8.00%|
|Jan 16||Wide Bands||Range Expansion||-8.00%|
|Jan 16||Oversold Stochastic||Weakness||-8.00%|
|Jan 15||Inside Day||Range Contraction||-11.54%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SESN news...
|52 Week High||3.5|
|52 Week Low||0.68|
|200-Day Moving Average||1.8526|
|50-Day Moving Average||1.3676|
|20-Day Moving Average||0.993|
|10-Day Moving Average||0.796|
|Average True Range||0.1306|
|Chandelier Exit (Long, 3 ATRs )||1.1582|
|Chandelier Exit (Short, 3 ATRs )||1.0718|
|Upper Bollinger Band||1.4794|
|Lower Bollinger Band||0.5066|
|Percent B (%b)||0.19|
|MACD Signal Line||-0.1741|
|Market Cap||10.62 Million|
|Num Shares||15.4 Million|
|Price-to-Earnings (P/E) Ratio||6.27|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||0.83|
|Resistance 3 (R3)||0.84||0.80||0.80|
|Resistance 2 (R2)||0.80||0.77||0.80||0.79|
|Resistance 1 (R1)||0.75||0.75||0.73||0.74||0.79|
|Support 1 (S1)||0.66||0.68||0.64||0.65||0.59|
|Support 2 (S2)||0.62||0.66||0.62||0.59|
|Support 3 (S3)||0.57||0.62||0.58|
|Support 4 (S4)||0.56|